Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes

Allen "Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study" Hepatology (2018) 10.1002/hep.29546

[3]

Lazarus "NAFLD – sounding the alarm on a silent epidemic" Nat Rev Gastroenterol Hepatol (2020) 10.1038/s41575-020-0315-7

[4]

Targher "The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments" Nat Rev Gastroenterol Hepatol (2021) 10.1038/s41575-021-00448-y

[5]

Ampuero "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH" J Hepatol (2020) 10.1016/j.jhep.2020.02.028

[6]

Byrne "NAFLD: a multisystem disease" J Hepatol (2015) 10.1016/j.jhep.2014.12.012

[7]

Adams "Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases" Gut (2017) 10.1136/gutjnl-2017-313884

[8]

NAFLD as a driver of chronic kidney disease

Christopher D. Byrne, Giovanni Targher

Journal of Hepatology 2020 10.1016/j.jhep.2020.01.013

[9]

Alexander "Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from a matched cohort study of 18 million European adults" BMJ (2019) 10.1136/bmj.l5367

[10]

Zhou "Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis" Eur J Gastroenterol Hepatol (2018) 10.1097/meg.0000000000001075

[11]

Pennisi "Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis" Aliment Pharmacol Ther (2022) 10.1111/apt.16763

[12]

Sanyal "NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease" N Engl J Med (2021) 10.1056/nejmoa2029349

[13]

Shili-Masmoudi "Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease" Liver Int (2020) 10.1111/liv.14301

[14]

Petta "Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease" Clin Gastroenterol Hepatol (2021) 10.1016/j.cgh.2020.06.045

[15]

Mantovani "Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis" Gut (2022) 10.1136/gutjnl-2020-323082

[16]

Aubert "Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus" Nephrol Dial Transplant (2022) 10.1093/ndt/gfab176

[17]

Cusi Endocr Pract (2022) 10.1016/j.eprac.2022.03.010

[18]

Sberna Diabet Med (2018) 10.1111/dme.13565

[19]

Blank "Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination" Sci Rep (2020) 10.1038/s41598-020-75227-x

[20]

Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 75(3); 659–89. 10.1016/j.jhep.2021.05.025

[21]

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Peter J. Eddowes, Magali Sasso, Michael Allison et al.

Gastroenterology 2019 10.1053/j.gastro.2019.01.042

[22]

Cardoso "Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study" Cardiovasc Diabetol (2021) 10.1186/s12933-021-01388-2

[23]

de Sousa Magalhães "Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients" Clin Res Hepatol Gastroenterol (2021) 10.1016/j.clinre.2020.11.010

[24]

Mantovani "Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis" Lancet Gastroenterol Hepatol (2021) 10.1016/s2468-1253(21)00308-3

[25]

Alon "Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis" Eur J Prev Cardiol (2022) 10.1093/eurjpc/zwab212

[26]

Zhou "Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis" Hepatol Commun (2018) 10.1002/hep4.1155

[27]

Villanova "Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease" Hepatology (2005) 10.1002/hep.20781

[28]

Planas A, Simó-Servat O, Bañeras J, Sánchez M, García E, Ortiz ÁM, et al. Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes. Acta Diabetol, 58; 1403–12. 10.1007/s00592-021-01735-5

[29]

Simó "Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study" BMJ Open Diab Res Care (2019) 10.1136/bmjdrc-2019-000845

[30]

American Diabetes Association. 2021. “2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021.” Diabetes Care 44 (Suppl. 1): S15–33. 10.2337/dc21-s002

[31]

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–276.

[32]

Nambi "Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study" J Am Coll Cardiol (2010) 10.1016/j.jacc.2009.11.075

[33]

Kramer "Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis" BMJ (2013) 10.1136/bmj.f1654

[34]

Ekstedt "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up" Hepatology (2015) 10.1002/hep.27368

[35]

McGlinchey "Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease" JHEP Rep (2022) 10.1016/j.jhepr.2022.100477

[36]

Boursier "Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications" Clin Gastroenterol Hepatol (2022)

[37]

Talens "What do we know about inequalities in NAFLD distribution and outcomes? A scoping review" J Clin Med (2021) 10.3390/jcm10215019

[38]

Altobelli "Lifestyle risk factors for type 2 diabetes mellitus and national diabetes care systems in European countries" Nutrients (2020) 10.3390/nu12092806

[39]

Yip "Geographical similarity and differences in the burden and genetic predisposition of NAFLD" Hepatology (2022)

Metrics

4

Citations

39

References

Details

Published: Nov 01, 2023
Vol/Issue: 46(9)
Pages: 682-691
License: View

Authors

Diabetes and Metabolism Research Unit; Vall d'Hebron Research Institute; Barcelona, and CIBERDEM-Instituto de Salud Carlos III; Madrid; Spain

Nephrology and Kidney Transplantation Research Group, Nephrology Department, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, 08035 Barcelona, Spain

Diabetes and Metabolism Research Unit; Vall d'Hebron Research Institute; Barcelona, and CIBERDEM-Instituto de Salud Carlos III; Madrid; Spain

I

Ignacio Ferreira-González

Cite This Article

Jesús Rivera-Esteban, Mònica Pons, Alejandra Planas, et al. (2023). Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes. Gastroenterología y Hepatología, 46(9), 682-691. https://doi.org/10.1016/j.gastrohep.2022.11.001

Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes

You May Also Like